Valence ロゴ
人気
ログイン

ウォッチリストに追加

Vera Therapeutics Inc.

NasdaqGM: VERA · リアルタイム株価 · USD
32.28
+0.65 (2.06%)
終値時点： Aug 18, 2026, 3:59 PM
32.00
-0.87%
寄り付き前: 4:00 AM

Vera Therapeutics Inc. (VERA) Stock Price, Analysis & Data

2.06%
買気配n/a
時価総額2.33B
売上高（TTM）n/a
純利益（TTM）-401.9M
ベータ0.95
EPS（TTM）-5.99
PER（TTM）n/a
予想PER-7.31
PBR（TTM）5.70
PSR（TTM）n/a
Earnings DateNov 5, 2026
売気配n/a
出来高1,013,349
平均出来高（20日）1,961,464
始値31.31
前日終値31.63
当日レンジ31.31 - 32.35
52週レンジ21.15 - 56.05
アナリストStrong Buy
目標株価79 (144.73%)
配当n/a
権利落ち日n/a

VERAについて

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immuno...

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 May 14, 2021
従業員数 361
上場取引所 NasdaqGM
ティッカー VERA
ウェブサイト https://veratx.com
企業情報の全文

業績

2025年のVera Therapeuticsの売上高は0で、前年の0からundefined%の増加でした。 利益は-299.62Mで、96.92%の増加でした。

財務諸表

アナリスト予想

14件のアナリスト評価によると、VERA株の平均レーティングは「Strong Buy」です。12か月後の目標株価は79で、直近株価から144.73%の上昇余地となります。

株価予想

決算サプライズ

Vera TherapeuticsはAug 10, 2026に四半期決算を発表しました：
  • 売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.
  • EPSは -1.52 で、予想を上回りました 0.07, うち -26.67% の前年比減少.

    • 次回決算発表

    Vera Therapeutics Inc.の決算発表予定日は Nov 5, 2026, 取引時間中の予定です。
    アナリストの売上高予想は ... アップグレード
    news image

    1か月前 · MarketBeat

    Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch

    Vera Therapeutics (NASDAQ:VERA) said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease prog...

    news image

    1か月前 · Simply Wall St.

    Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)?

    Vera Therapeutics recently received FDA accelerated approval for TRUTAKNA™ (atacicept-vymj), a first-in-class dual BAFF/APRIL inhibitor to reduce proteinuria in adults with primary IgA nephropathy at ...

    news image

    1か月前 · Simply Wall St.

    Vera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA Approval

    Vera Therapeutics (VERA) has drawn fresh attention after the US Food and Drug Administration granted accelerated approval for TRUTAKNA to treat adults with IgA nephropathy who are at risk for disease ...

    news image

    1か月前 · Simply Wall St.

    Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% Run

    Vera Therapeutics has delivered a strong 184.9% return over the past 5 years, yet its valuation checks and current market multiples point to a stock that may now be leaning expensive rather than clear...

    news image

    1か月前 · MT Newswires

    Sector Update: Healthcare Stocks Gain Late Afternoon

    Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S

    2ページ中1ページ